Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19840378 | 0.95 | SIGMAR1 (0.55) | SIGMAR1CHRNB2CHRNA4USP2TP53 | |
| SCHEMBL5021340 | 0.90 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4USP2TP53 | |
| SCHEMBL5021338 | 0.90 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4USP2TP53 | |
| SCHEMBL5021346 | 0.90 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4USP2TP53 | |
| SCHEMBL5021337 | 0.83 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4USP2TP53 | |
| SCHEMBL5021336 | 0.83 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4USP2TP53 | |
| SCHEMBL5021339 | 0.83 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4USP2TP53 | |
| SCHEMBL5021317 | 0.83 | SIGMAR1 (0.42) | SIGMAR1CHRNB2CHRNA4MAPK1MAPT | |
| SCHEMBL5021324 | 0.83 | SIGMAR1 (0.42) | SIGMAR1CHRNB2CHRNA4MAPK1MAPT | |
| SCHEMBL5021318 | 0.83 | SIGMAR1 (0.42) | SIGMAR1CHRNB2CHRNA4MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | SIGMAR1 2803/4885CHRNB2 1935/4885CHRNA4 2618/4885 |
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | SIGMAR1 1414/4885CHRNB2 1776/4885CHRNA4 2463/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | SIGMAR1 1414/4885CHRNB2 1776/4885CHRNA4 2463/4885 |
| US-20180127426-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | SIGMAR1 1414/4885CHRNB2 1776/4885CHRNA4 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.